Trial Profile
A double-blind, placebo-controlled, single and multiple ascending dose phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of CCX507-B in healthy male and female subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2014
Price :
$35
*
At a glance
- Drugs CCX 507 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors ChemoCentryx
- 22 Oct 2014 Results presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology.
- 21 Oct 2014 Results published in a ChemoCentryx media release.
- 28 May 2014 New trial record